These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Peptide vaccines for cancer. Weber J Cancer Invest; 2002; 20(2):208-21. PubMed ID: 11901542 [TBL] [Abstract][Full Text] [Related]
3. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide. Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565 [TBL] [Abstract][Full Text] [Related]
4. Melanoma vaccines: prim and proper presentation. Timmerman JM; Levy R Nat Med; 1998 Mar; 4(3):269-70. PubMed ID: 9500593 [No Abstract] [Full Text] [Related]
5. Peptide vaccine trials for melanoma: preclinical background and clinical results. Talebi T; Weber JS Semin Cancer Biol; 2003 Dec; 13(6):431-8. PubMed ID: 15001162 [No Abstract] [Full Text] [Related]
16. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. Slingluff CL; Petroni GR; Olson W; Czarkowski A; Grosh WW; Smolkin M; Chianese-Bullock KA; Neese PY; Deacon DH; Nail C; Merrill P; Fink R; Patterson JW; Rehm PK J Clin Oncol; 2008 Oct; 26(30):4973-80. PubMed ID: 18809608 [TBL] [Abstract][Full Text] [Related]
17. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. Melssen MM; Pollack KE; Meneveau MO; Smolkin ME; Pinczewski J; Koeppel AF; Turner SD; Sol-Church K; Hickman A; Deacon DH; Petroni GR; Slingluff CL Cancer Immunol Immunother; 2021 Aug; 70(8):2151-2164. PubMed ID: 33454795 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165 [TBL] [Abstract][Full Text] [Related]
19. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266 [TBL] [Abstract][Full Text] [Related]